Mark Jacobson
Chief Operating Officer presso AXSOME THERAPEUTICS, INC.
Patrimonio netto: - $ in data 31/03/2024
Profilo
Mark L.
Jacobson is currently the Chief Operating Officer at Axsome Therapeutics, Inc. He previously worked as the Director of Corporate Development at Stemline Therapeutics, Inc. from 2009 to 2014.
Mr. Jacobson received his graduate degree from The Trustees of Columbia University in The City of New York in 2010 and his undergraduate degree from Iowa State University in 2006.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 01/04/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Mark Jacobson
| Società | Posizione | Inizio |
|---|---|---|
| AXSOME THERAPEUTICS, INC. | Chief Operating Officer | 01/04/2014 |
Precedenti posizioni note di Mark Jacobson
| Società | Posizione | Fine |
|---|---|---|
| STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/03/2014 |
Formazione di Mark Jacobson
| The Trustees of Columbia University in The City of New York | Graduate Degree |
| Iowa State University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| AXSOME THERAPEUTICS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
- Borsa valori
- Insiders
- Mark Jacobson
